CytoDyn Inc.
CYDY · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.16 | -0.83 | -2.58 | 0.06 |
| FCF Yield | -0.65% | -1.34% | -1.31% | -2.56% |
| EV / EBITDA | -84.61 | -88.86 | -110.92 | -47.27 |
| Quality | ||||
| ROIC | 37.58% | 20.16% | 18.12% | -780.42% |
| Gross Margin | 0.00% | 0.07% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.44 | 0.95 | 1.04 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | 368,303.15% | 368,303.15% |
| Free Cash Flow Growth | 56.74% | -14.27% | -38.20% | -165.92% |
| Safety | ||||
| Net Debt / EBITDA | -7.11 | -3.13 | -3.12 | -7.09 |
| Interest Coverage | -6.63 | -5.00 | -3.19 | -2.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -318,937.50 | -330,600.43 | -272,286.00 | -320,490.00 |